Lyrica found to alleviate diabetes pain in feet and hands
ALEXANDRIA, Va. A review of previous studies by the journal Diabetes Care indicates that Pfizer’s seizure drug Lyrica is safe and effective for relieving diabetic neuropathy, the pain that diabetics often experience in their feet and hands, as reported by Reuters.
The analysis of data involved seven studies of the drug, with dosages of 150, 300, and 600 milligrams daily and study durations from five to 13 weeks.
Roy Freeman of Harvard Medical School in Boston and colleagues report that “pregabalin, (Lyrica), significantly reduced pain and pain-related sleep interference” with all three dosages when divided into three pills taken throughout the day. Only the highest dosage was effective when divided into two pills.
With the 600 mg daily dose, it typically took four days for a sustained reduction in pain. With the 300 and 150 mg daily doses, it took five days and 13 days, respectively.
While the 600 mg dose was the most effective, it was also the most likely to cause side effects. Common side-effects included dizziness, sleepiness, and swelling in the legs and arms.
BMS settles with EPA over environmental issues
NEW YORK Bristol-Myers Squibb has agreed to resolve Clean Air Act violations by reducing its emissions of ozone-depleting refrigerants at multiple facilities, paying about $3.65 million to upgrade some facilities.
The company’s settlement with the Environmental Protection Agency requires it to retire or retrofit 17 industrial refrigeration units by July 2009 at facilities in Mt. Vernon and Evansville, Ind.; Hopewell, N.J.; and Humacao and Mayaguez, Puerto Rico, the EPA said.
The units use hydrochlorofluorocarbons as refrigerants in the industrial process or in air conditioners. BMS agreed to change the units to use only non-ozone-depleting refrigerants, the EPA said.
The settlement, filed in the U.S. District Court for the Southern District of Indiana, also requires the company to retire two comfort-cooling units at its New Brunswick, N.J., plant and connect the air conditioners to the company’s new centralized refrigeration system. The new system uses water-chilled coolers to minimize the use of chemical agents.
The company also must take steps to ensure compliance with EPA regulations at 13 of its facilities and pay $127,000 in fines. It also must submit three annual reports to each EPA region describing actions it has taken to comply with the settlement.
Following an EPA information request concerning its Evansville, Indiana, facility, BMS voluntarily audited 25 other facilities and reported potential violations. According to the EPA, the audit found potential violations at facilities in Connecticut, Indiana, Massachusetts, Michigan, New Jersey, New York and Puerto Rico.
BMS said it will continue to monitor all sites.
Vical bird flu vaccine successful in phase I
SAN DIEGO A phase I study by Vical has found that its vaccine against avian influenza can protect against the virus, the company announced Thursday.
The double-blind, placebo-controlled study examined 100 volunteers ages 18 to 45 who received two injections of the vaccine and found that 50 to 67 percent of patients receiving 0.5mg and 1mg doses of the vaccine had immune responses that could protect against the H5N1 strain of avian flu.
The vaccine is made from DNA derived from plasmids, small pieces of genetic material, and designed to provoke an immune response.
H5N1 originated in Asia and spread to Europe, the Middle East and Africa. Of 385 people infected, 243 have died. Experts fear it could mutate into a form transmissible between humans and cause a global pandemic that would kill millions.